Current Status and Challenges of Oncolytic Virotherapy for the Treatment of Glioblastoma
Despite decades of research and numerous clinical trials, the prognosis of patients diagnosed with glioblastoma (GBM) remains dire with median observed survival at 8 months. There is a critical need for novel treatments for GBM, which is the most common malignant primary brain tumor. Major advances...
Saved in:
Main Authors: | Mason J. Webb (Author), Ugur Sener (Author), Richard G. Vile (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2023-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Progress of oncolytic virotherapy for neuroblastoma
by: Xiao-Tong Chen, et al.
Published: (2022) -
The combination therapy of oncolytic virotherapy
by: Yue Wang, et al.
Published: (2024) -
The Current Status, Challenges, and Future Potential of Therapeutic Vaccination in Glioblastoma
by: Bryan J. Neth, et al.
Published: (2023) -
Strategies for Advanced Oncolytic Virotherapy: Current Technology Innovations and Clinical Approaches
by: Qing Ji, et al.
Published: (2022) -
Talimogene laherparepvec: First in class oncolytic virotherapy
by: Robert M. Conry, et al.
Published: (2018)